论文部分内容阅读
目的:探讨替罗非班对ST段抬高急性心肌梗死患者直接经皮冠状动脉内介入治疗(PCI)中冠状动脉内血栓的影响。方法:79例患者,随机分为试验组(替罗非班+PCI,34例)和对照组(直接PCI,45例)。观察住院期间主要心血管事件(MACE)发生率,冠状动脉内血栓和使用替罗非班的不良反应。结果:与对照组相比,试验组于术前应用替罗非班使PCI术前梗死相关血管(IRA)内血栓存在比例明显降低(P<0.05);试验组出血发生率较对照组有增多趋势(P>0.05)。结论:早期使用血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂替罗非班,可以明显减少STEMI梗死相关血管内血栓的发生率。
Objective: To investigate the effect of tirofiban on coronary thrombosis in patients undergoing direct percutaneous coronary intervention (PCI) with ST-segment elevation acute myocardial infarction. Methods: Totally 79 patients were randomly divided into experimental group (tirofiban + PCI, 34 cases) and control group (direct PCI, 45 cases). The incidence of major cardiovascular events (MACE) during hospitalization, thrombus in the coronary artery, and adverse reactions with tirofiban were observed. Results: Compared with the control group, Tirofiban preoperatively reduced the proportion of thrombus in infarction-related blood vessels (IRA) preoperatively in the experimental group (P <0.05); the incidence of bleeding in the experimental group was significantly higher than that in the control group Trend (P> 0.05). Conclusion: The early use of platelet glycoprotein Ⅱb / Ⅲa receptor antagonist tirofiban can significantly reduce the incidence of STEMI infarction-related intravascular thrombosis.